Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Eton Pharmaceuticals to similar companies based on the strength of its dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Profitability
This table compares Eton Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eton Pharmaceuticals | 35.35% | 104.82% | 43.09% |
| Eton Pharmaceuticals Competitors | -2,400.61% | -215.91% | -15.58% |
Earnings and Valuation
This table compares Eton Pharmaceuticals and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Eton Pharmaceuticals | $79.95 million | -$4.60 million | 41.54 |
| Eton Pharmaceuticals Competitors | $3.56 billion | $3.18 billion | 557.99 |
Eton Pharmaceuticals’ rivals have higher revenue and earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Eton Pharmaceuticals has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals’ rivals have a beta of -0.05, indicating that their average share price is 105% less volatile than the S&P 500.
Institutional and Insider Ownership
27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Eton Pharmaceuticals and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eton Pharmaceuticals | 0 | 1 | 5 | 0 | 2.83 |
| Eton Pharmaceuticals Competitors | 7847 | 13801 | 25829 | 1039 | 2.41 |
Eton Pharmaceuticals presently has a consensus target price of $79.75, indicating a potential upside of 27.14%. As a group, “Pharmaceuticals” companies have a potential upside of 26.34%. Given Eton Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eton Pharmaceuticals is more favorable than its rivals.
Summary
Eton Pharmaceuticals beats its rivals on 8 of the 13 factors compared.
About Eton Pharmaceuticals
Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
